About Us

Daniel Kennedy joined Resolution Therapeutics in September 2025. He previously served as Vice President, Business Development at Immunocore plc (IMCR), a fully integrated UK-based biotechnology company. Within his functions of business development and capital raising, Dan played a pivotal role in advancing Immunocore’s platform of soluble, bi-specific T-Cell Receptors (TCRs), including Kimmtrak (tebentafusp), approved in over 20 countries for the treatment of metastatic uveal melanoma.

During his five-year tenure at Immunocore, Dan led partnering and alliance management functions, in- and out-licensing, research collaborations, exclusive global commercial distribution, and clinical combinations. These efforts supported Immunocore’s discovery, development, translational medicine, and commercial teams. On the corporate finance front, he led or actively took a leadership role in the company’s initial public offering (IPO), debt financings, and convertible debt offering. In response to Immunocore’s growing cash position, amid global banking disruption, Dan also assumed the role of interim Treasurer, entrusted with safeguarding and growing Immunocore’s cash reserves, implementing effective currency hedges, and ensuring an optimal currency basket to support operations.

Prior to his tenure at Immunocore, Dan led Business Development and Alliance Management at Achillion Pharmaceuticals (ACHN). Working closely with the Executive Leadership Team, he directed business development initiatives that culminated in Achillion’s acquisition by Alexion Pharmaceuticals (ALXN) for $930 million in cash, plus up to $300 million in contingent value rights. Dan was a core member of the post-acquisition integration effort.

Dan has extensive experience in Big Pharma, first at Schering and then at GSK, where he held diverse roles spanning business development transactions for R&D, alliance management, global corporate development, US commercial marketing, brand launch pricing, and payer contracting.

Dan holds an MBA in finance from New York University’s Stern School of Business and a Bachelor of Science degree from Fairleigh Dickinson University, Madison, New Jersey. Dan is a dual US/UK citizen and lives in Philadelphia, PA.

Lucy Singah joined Resolution Therapeutic as the Chief Financial Officer in September 2025.

Lucy brings deep financial expertise, strategic vision, and a passion for purpose-driven business. Formerly fractional CFO at Echopoint Medical, a medtech start-up developing advanced cardiac diagnostic devices, she led financial planning, payment system implementation, and board-level support during key development stages of the company.  Simultaneously Lucy was CFO at impact investment in indigenous Amazon communities with Amazonia Impact Ventures.  Previous to that Lucy was the Finance Director at another medtech start up, Axis Spine Technologies developing spinal implants, overseeing financial operations, ERP system rollout, and multiple successful fundraising rounds.

In Lucy’s earlier career, she spent 11 years at GSK plc in various roles including Corporate Development during major acquisitions, establishing ViiV Healthcare.  She worked in Investor Relations, as well as finance leadership in procurement and consumer healthcare. She started her career in Ernest Young’s Transaction Advisory Services after graduating in Management Studies from the University of Nottingham.

Cliff Brass is an expert in clinical development with special expertise in liver disease  and over 25 years of experience in Pharma. Most recently Dr. Brass was Vice President, Head of Clinical Sciences for Hepatology, Gastroenterology and Transplantation in Global Drug Development at Novartis.  Prior to that he worked at Schering-Plough/Merck and led medical affairs efforts in HCV before transitioning to lead multiple programs in drug development encompassing more than 30 NDAs/label changes in the US, EU and Japan.  Dr. Brass earned his Bachelor of Arts degree in Biochemical Sciences at the Harvard College, and his MD and PhD (Pharmacology) degrees at the Mount Sinai School of Medicine in New York City. He completed his Internal Medicine Residency at the University of Chicago Hospitals and Clinics and his Gastroenterology and Hepatology Fellowship training at Brigham & Women’s Hospital/Harvard Medical School.  He then became a faculty member in the Department of Medicine, Division of Gastroenterology and Biochemistry & Biophysics Departments at the University of Pennsylvania where he treated patients and ran a nationally funded research laboratory focused on the mechanisms of liver injury, and was Head of the Liver Study unit and Medical Director of the Liver Transplant Program. Dr Brass has published over 85 peer reviewed articles and more than 200 abstracts, primarily in the field of Hepatology, in both the areas of clinical and basic science research. He is named on 15 patents relating to drug development in liver disease. He is currently on the Project Executive of LITMUS, the IMI NASH Biomarker consortium, and a visiting professor at Newcastle University.

Lara is the SVP of Research and Translational Science and a member of the founding team at Resolution Therapeutics. She achieved a Bachelor degree in Medical and Pharmaceutical Biotechnology, followed by a Master in Cellular and Molecular Medical Biotechnology from the San Raffaele University in Milan, Italy. She then successfully obtained a PhD in Cellular and Molecular Immunology, as part of a programme run by the San Raffaele University in collaboration with the Open University (Milton Keynes, UK). Her long-term research interest is the role of inflammation in tissue repair. She then moved to the University of Edinburgh, where she studied the role of macrophage phagocytosis in acute and chronic liver injury, under the supervision of Prof John Iredale (2013-2016) and Prof Stuart Forbes (2016-2020). She is author of more than 20 papers in international peer-reviewed journals. Outside the lab, Lara is passionate about teaching, science communication and equality, and is a keen hiker.

Louise Rowe joined Resolution Therapeutics as VP, Operations in April 2026, bringing more than 30 years of drug development experience spanning gene therapy in rare diseases, small molecules, biologics and consumer health, with global assignments across the US, Europe and Asia.

Most recently, Louise served as VP, Program & Alliance Management at AviadoBio, where she led the global program team for AVB-101, a novel intra-thalamic AAV gene therapy for frontotemporal dementia caused by progranulin mutations, from pre-clinical through first-in-human clinical trial. During her tenure she drove IND clearance for AVB-101 and oversaw the opening of the ASPIRE-FTD Phase 1/2 clinical study at sites in EU, UK & US.

Prior to AviadoBio, Louise was Program Lead for Libmeldy and VP, Clinical Operations & Data Management at Orchard Therapeutics, where she led the global program team to deliver Libmeldy, a lentiviral gene therapy for metachromatic leukodystrophy, through marketing authorisation and reimbursement in Europe. She also established the strategic vision for clinical operations across Orchard’s broader gene therapy portfolio.

Earlier in her career she held Global Program Team Director roles at Novartis across Women’s Health & Urology (US), Respiratory (China), and Immunology & Infectious Diseases (Basel), including work on Cosentyx®.

Louise holds a BSc (Hons) in Applied Biology and is a recipient of the Novartis Ovations Award for Business Excellence.

Eli is the VP of Intellectual Property & Technology Strategy at Resolution Therapeutics, operating at the intersection of biotechnology innovation, commercial execution, and legal protection His mandate spans building and defending Resolution’s patent portfolio, aligning IP milestones with the company’s R&D roadmap, and maximising asset value for investors and partners.

Eli brings over 15 years of senior leadership in biotech and pharma.   Prior to joining Resolution Therapeutics, Eli was part of the senior leadership team of Tropic Biosciences, serving as VP Intellectual Property. While at Tropic, Eli founded the IP function from the ground up – building the team, establishing trade secret policy, establishing the IP strategy, expanding the patent portfolio, and leading IP due diligence through multiple successful investment rounds. He also structured the complex IP licensing arrangements underpinning Tropic’s spin-out, Laverock Therapeutics. Earlier in his career, Eli held leadership positions including Principal Patent Counsel at Quark Pharmaceuticals and further held positions in leading private practice IP firms, with a focus on biotechnology and medical devices.

Eli has a strong scientific foundation, holding a PhD in Molecular Genetics and an MSc in Cell Biology from the Weizmann Institute of Science and having led pre-clinical research at Ben-Gurion University on an industry-funded peptide-based bone-regeneration programme. He also holds an MBA specialising in Bio-Medical Management.

Amir Hefni is the CEO of Resolution Therapeutics. Since being appointed in August 2023, Amir has worked with the team to take Resolution’s lead asset into clinic, and most recently the Company has been granted MHRA approval to commence a Phase I/II EMERALD study. Prior to joining Resolution, he was the Global Head of Cell and Gene Therapy at Novartis and had end to end responsibility for the platform. Previously, he was a Global Asset Head in Oncology at Ipsen and spent most of his career at Bristol-Myers Squibb with senior positions across US Oncology, General Management and Strategy & Operations for key markets. Amir holds a BSc and PhD in Pharmacology from King’s College London and an MBA from Warwick Business School.

Amol has over 25 years of experience in pharmaceutical development and manufacturing.  He spent 21 years in various roles at GlaxoSmithKline (GSK), most recently as Vice-President, Product Development and Supply for GSK’s Cell and Gene Therapy (CGT) CMC group.

Prior to CGT, Amol held positions of increasing responsibility within GSK’s Biopharm group and supported CMC development across the development lifecycle from pre-candidate selection to post commercial support.  Amol’s time in GSK included process and product development for several therapeutics in GSK’s portfolio.  Amol and his team successfully delivered GSK clinical and commercial medicines, including Arzerra, the first monoclonal antibody approval for GSK and Strimvelis which was one of the first ex-vivo autologous cell and gene therapy medicines approved by regulatory authorities.  Amol has a Bachelor’s degree in Pharmacy from the University of Bombay, a Ph.D. in Pharmaceutics from The Ohio State University, and post-doctoral training from University of Iowa.

Shazia is Resolution’s VP of People & Culture. Having held several global leadership roles reporting to the Board, Shazia is a results orientated HR leader seasoned at building robust people programs in line with the Corporate Strategy. She joined Resolution in March 2023, bringing with her over 25 years of life sciences industry experience.  Shazia partners closely with the Senior Leadership Team on all people matters to create a strong, inclusive and collaborative culture, driving the company values to achieve scientific excellence.

Prior to joining Resolution Therapeutics, Shazia was Head of Human Resources for Ergomed plc delivering the people elements of the business on its growth journey both organically and through M&A. She held a global role and built the HR infrastructure that served the needs of the business. She has experience of creating and leading Centres of Excellence in Talent Acquisition, Learning and Development, Total Rewards, HR Analytics and HR Business Partnering.

Prior to embarking on her HR journey Shazia started her career in ICON Clinical Research as a Clinical Research Associate. There she successfully held several positions within clinical operations, regulatory compliance and resource management before moving to PRA Health Sciences as an Associate Director within Resource Management gaining skills in change management, work force planning, staff utilisation, and resource realisation.

Shazia holds a BSc (Hons) and a DPhil in Medicinal Chemistry from the University of Sussex. Shazia lives in London with her 2 children.

Stuart is the Professor of Transplantation and Regenerative Medicine at the University of Edinburgh, the Director of the Centre for Regenerative Medicine, and a Consultant Hepatologist in the Scottish Liver Transplant Unit. He is also Director UKRMP The Engineered Cell Environment HUB. Stuart has pioneered the research of macrophage cell therapy for liver disease, elucidating the underlying biology of macrophages and applying this learning to the development of novel treatments for liver disease. Stuart trained in Medicine at the University of Edinburgh, undertook a PhD at Imperial College, and worked in London as a Hepatologist before returning to Edinburgh in 2006.

John is Director of Tissues, Cells and Advanced Therapeutics at the Scottish National Blood Transfusion service in Edinburgh and holds academic appointments at the University of Glasgow and University of Edinburgh. He holds an honours degree in Cell and Immunobiology from Aberdeen University and a PhD in Pathology from the University of Edinburgh. He has worked on the therapeutic use of immune cells for 30 years, including his early research in parasite-infected macrophages at Roslin Institute/University of Edinburgh and subsequent lectureship in tumour immunology at University of Glasgow. John worked worldwide in the Biotech industry for 11 years, developing reagents and techniques to drive the adoption of cellular therapies in a variety of disease settings. Since returning to Edinburgh in 2013, John has led process development and manufacturing for the MATCH trials for the use of macrophage cell therapy to treat liver cirrhosis.

Paul is the Chair of the Board of Resolution Therapeutics. Paul has over 35 years of experience in the life sciences industry, including leading business development and strategy in major pharmaceutical and biotechnology companies where he has a successful track record of partnering, M&A and financing. Paul is currently President and Chief Executive Officer of vTv Therapeutics, Inc. Most recently he served as President and CEO of eGenesis, Inc. from 2019-2022 and of Lycera Corp. from 2015-2019.  Prior to this, Paul held senior leadership positions at Sanofi, Teva Pharmaceuticals, TPG Biotech, Cerimon Pharmaceuticals, Inc. and ARIAD Pharmaceuticals. Paul also spent five years as Senior Vice President, and Head of Global Search and Evaluation, Business Development and Licensing for Novartis. Paul has been a Director on more than 35 private, public company, and non-profit Boards and is currently a member of the Board of Directors of Veeva Systems, Chair of the Board at Compugen Ltd., Longboard Pharmaceuticals, and Kaerus Bioscience. He is also on the Board of Spring Discovery, Inc, and AdhereTech Inc. He was, until recently, the Chairman of the Board of Pharming N.V. and recently spent 5 years on the Board of Ipsen, S.A. Additionally, he is on the Board of Directors of The Metropolitan Opera, The English Concert in America, and was a member of the Board of Trustees of Carnegie Hall. Most recently, he was nominated as Chairman of the Board of Trustees of Young Concert Artists, Inc. Paul holds a B.S. degree from the University of Maryland and completed post-graduate studies at the University of Maryland School of Medicine.

Stuart is the Professor of Transplantation and Regenerative Medicine at the University of Edinburgh, the Director of the Centre for Regenerative Medicine, and a Consultant Hepatologist in the Scottish Liver Transplant Unit. He is also Director UKRMP The Engineered Cell Environment HUB. Stuart has pioneered the research of macrophage cell therapy for liver disease, elucidating the underlying biology of macrophages and applying this learning to the development of novel treatments for liver disease. Stuart trained in Medicine at the University of Edinburgh, undertook a PhD at Imperial College, and worked in London as a Hepatologist before returning to Edinburgh in 2006.

1. Gonzalo is a Principal at Syncona and sits on the boards of Resolution Therapeutics and Yellowstone Biosciences. He was closely involved in the foundation of both companies, including their strategic and operational set-up, through hands-on membership of their founding leadership teams.

   Previously, Gonzalo was a Project Leader at Boston Consulting Group where, amongst other responsibilities, he supported clients in the biopharmaceuticals industry across the entire value chain. Gonzalo has an interdisciplinary background with a PhD in Protein Biophysics from the University of Cambridge, involving an EMBO Short-Term Fellowship in Cell Biology at Harvard Medical School, and an undergraduate and Master’s degree in Physics also from the University of Cambridge.

Amir Hefni is the CEO of Resolution Therapeutics. Since being appointed in August 2023, Amir has worked with the team to take Resolution’s lead asset into clinic, and most recently the Company has been granted MHRA approval to commence a Phase I/II EMERALD study. Prior to joining Resolution, he was the Global Head of Cell and Gene Therapy at Novartis and had end to end responsibility for the platform. Previously, he was a Global Asset Head in Oncology at Ipsen and spent most of his career at Bristol-Myers Squibb with senior positions across US Oncology, General Management and Strategy & Operations for key markets. Amir holds a BSc and PhD in Pharmacology from King’s College London and an MBA from Warwick Business School.

Edward Hodgkin is a Managing Partner of Syncona Investment Management Ltd. He is currently the Chair of Mosaic Therapeutics and a Board member of Resolution Therapeutics and OMass Therapeutics. He was also previously the first CEO and a board member of Autolus Therapeutics (NASDAQ:AUTL), and the former CEO of Resolution Therapeutics. Within the Syncona life science team, he is involved in creation of new businesses and then fills executive roles within those companies to make them operational. Prior to Syncona, he was CEO of Biotica Ltd (Cambridge, UK), President & Chief Business Officer of BrainCells Inc (San Diego, CA), and VP, Business Development & Marketing at Tripos Inc (St Louis, MO). Ed’s early career was spent in research and management positions with Wyeth-Ayerst Inc and British Biotech. He holds a degree and DPhil in Chemistry from the University of Oxford, and is a former Chairman of the BIA, the UK’s trade association for innovative life science companies.

Bill Symonds joined Enzyvant as CEO in 2022. Dr. Symonds also serves as the Chief Executive Officer of Altavant Sciences since its inception in August 2018. Previously, Dr. Symonds was a member of the founding management team at Roivant Sciences, Inc. where he served as Roivant’s Chief Development Officer.

In that role, Dr. Symonds crafted the research and development plans for many products including rodatristat ethyl, Altavant’s lead asset for the treatment of pulmonary arterial hypertension and was instrumental in the licensing and early development of RETHYMIC®. Earlier in his career, Dr. Symonds held senior positions at several pharmaceutical companies including Pharmasset, Inc. and Gilead Sciences, Inc. Based on their early success at Pharmasset, leading the development of Sovaldi® for hepatitis C virus infection, Dr. Symonds and his team were brought into Gilead after its acquisition of Pharmasset, where he continued to advance Sovaldi® through to FDA approval. Previously, he worked at GlaxoSmithKline and its predecessor companies on numerous approved medicines for HIV infection including Ziagen®, Agenerase® and Epzicom®.

He has authored or co-authored over 35 clinical articles and is named on nine patents related to the composition of matter and methods of use of drugs for hepatitis C infection.

Susan is an observer to the board on behalf of the University of Edinburgh. Susan is the Head of Business Development for the College of Medicine and Veterinary Medicine at Edinburgh Innovations with substantial experience in both University and commercial life science research environments. Susan holds a PhD in Biomedical Science from the University of Aberdeen.

Alessio is an Analyst at Syncona.

Prior to joining as an Analyst, Alessio was an Intern at Syncona through the Windsor Fellowship programme. He also interned in the Strategy & Operations team at Syncona portfolio company, Resolution Therapeutics.

Alessio holds a PhD in Biological Sciences from the University of Southampton where he combined biophysics and glycobiology in the study of HIV-1 vaccine design.

Director, Center for Cell Therapy and Transplant
University of Pennsylvania

Jodi Fisher Horowitz Professor of Leukemia Care Excellence

Mr. and Mrs. Ronald F. Kinney Executive Dean of Research

Carol M. Gatton Professor of Digestive Disease Research, Honoring Peter Carryer, M.D.

Mayo Clinic, Rochester MN

Chair of Translational Liver Research
University of Edinburgh

Mitchell T. Rabkin, M.D. Chair; Professor of Medicine; and Faculty Dean
Harvard Medical School

Chief Academic Officer, Beth Israel Lahey Health and Beth Israel Deaconess Medical Center

Director of the Stravitz-Sanyal Institute for Liver Disease and Metabolic Health
Virginia Commonwealth University

Distinguished University Professor
Medical University South Carolina

Associate Professor, MM Internal Medicine – Gastroenterology
University of Michigan

Chief, Division of Gastroenterology and Hepatology
Weill Cornell Medical College

Vincent Astor Distinguished Professor of Medicine.

Professor Gastroenterolgy & Hepatology
University of Vienna